Pharma lobby groups are urging for changes to the centralized no-objection certification (NOC) for drug exports due to a significant export decline. The requirement for approvals from importing countries or Indian regulators has increased trade diversions. Industry experts are calling for a review of the provision, citing burdens on exporters and potential...
Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr
Nectar Lifesciences will sell its active pharmaceutical ingredients, formulation, and menthol business assets to Ceph Lifesciences for ₹1,290 crore. This strategic move involves a Business Transfer Agreement for the core API and formulation business at ₹1,270 crore and an Asset Purchase Agreement for the menthol business at ₹20 crore.
from Healthcare/Biotech-Industry-Economic...
Aster DM Healthcare sets sights on smaller cities to expand play, grab top spot
Aster DM Healthcare, after merging with Quality Care India, aims to become India's largest healthcare chain, surpassing Apollo Hospitals. Fueled by Blackstone's backing, Aster plans to increase bed capacity to 13,600 and expand into central India. The company anticipates improved margins through supply chain optimization and increased occupancy, targeting...
Delhi HC upholds order to restrain Rajasthan Aushdhalaya from making and selling medicines under Liv-333 name
The Delhi High Court has upheld a previous order restraining Rajasthan Aushdhalaya from selling medicines under the name Liv-333 or similar names, due to trademark infringement of Himalaya's Liv.52. The court found Rajasthan Aushdhalaya's adoption of 'Liv-333' as intentionally similar to capitalize on Himalaya's established reputation.
from Healthcare/Biotech-Industry-Economic...
Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course
The Indian Medical Association (IMA) has strongly criticised the Maharashtra Medical Council's (MMC) recent notification allowing homeopaths to prescribe modern medicines after a brief pharmacology course. IMA views this as misleading to patients and a dilution of modern medical practices. They highlight existing legal challenges and a stay order from...
Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy
Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats osteoporosis and bone loss. This approval follows a similar authorization from the European Commission....
Union Health Minister JP Nadda, Delhi CM Rekha Gupta flag off Ayushman Bharat registration vans in New Delhi
Union Minister JP Nadda and Delhi CM Rekha Gupta launched Ayushman Bharat registration vans in New Delhi. Nadda criticized AAP for not utilizing allocated funds for the scheme. He praised Ayushman Arogya Mandir, contrasting it with AAP's Mohalla Clinics. Rekha Gupta and ministers inaugurated Ayushman Arogya Mandirs in Delhi. Ashish Sood distributed...
DRDO, AIIMS-Rishikesh ink MoU for clinical trials in field of biomedical devices
DRDO's Defence Institute of Physiology and Allied Sciences (DIPAS) and AIIMS, Rishikesh, have partnered to conduct clinical trials and advanced research. The collaboration aims to develop biomedical devices and supplements enhancing human performance in extreme environments. This joint effort will focus on creating products and technologies to mitigate...
Niti to review concerns over pharma quality
Niti Aayog is addressing growing quality concerns in India's pharmaceutical industry by convening industry experts for discussions. The aim is to analyze the current state, understand challenges, and improve the quality of Indian pharmaceutical products to meet global standards. A meeting chaired by VK Paul will propose recommendations to ensure alignment...
Lupin launches Ipratropium Bromide nasal spray in US
Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, bioequivalent to Boehringer Ingelheim's Atrovent, target rhinorrhea associated with allergies, nonallergic rhinitis, and the common cold. The annual sales for Ipratropium Bromide nasal solution (Atrovent) in the US were approximately...
CBI searches premises of Pharmacy Council of India chief in corruption case
The CBI has booked Pharmacy Council of India President Montu M. Patel for alleged corruption and irregularities in pharmacy college approvals, conducting searches at his premises. Investigations revealed manipulated inspections, favouritism towards specific institutions, and electoral manipulation before Patel's presidential election. Approvals were...
Hassan heart attack death cases: India’s top drugmakers rally behind Covid vaccines
Amid over 20 sudden heart attack deaths in Karnataka’s Hassan district, leading drugmakers have defended Covid vaccines on social media. Industry leaders including Dilip Shanghvi, Pankaj Patel, Satish Reddy, and Samir Mehta stressed there is no scientific link between the deaths and vaccination. The Karnataka health department has formed an expert...
COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPA
The Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testing and crucial role in combating the pandemic. IPA Secretary General Sudarshan Jain highlighted the Indian pharmaceutical industry's knowledge-driven nature and its significant contribution to global vaccine production,...
Karnataka CM's remarks on covid vaccines 'factually incorrect,' says Biocon chief Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw refuted Karnataka CM Siddaramaiah's claim. Siddaramaiah linked covid-19 vaccines to heart attack deaths in Hassan. Shaw stated the vaccines followed rigorous safety protocols. She said the vaccines saved lives. The Union Health Ministry dismissed Siddaramaiah's statement. Studies show no link between vaccines and sudden deaths....
Delhi HC seeks regulator's reply after PIL questions Ozempic, Mounjaro nod
The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounjaro. A public interest litigation raised questions about safety data and clinical trials. The court wants the regulator to consult experts and manufacturers. Ozempic is available in the grey market, though not officially...
Auriga Research, SFRI ink pact to advance clinical research, AI-driven support for healthcare industry
Auriga Research partners with San Francisco Research Institute. The collaboration focuses on global clinical research. It will promote AI-integrated healthcare solutions. The partnership aims to expand access to wellness products in India, the US, and Africa. SFRI will support regulatory strategy and commercial partnerships. Both organizations will...
Cipla in talks to add new customers for its China factory, executive says
Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand...
Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy
Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via...
Apollo Hospitals to spin off digi health, pharmacy business
Apollo Hospitals is demerging its omnichannel pharma and digital health businesses into a new entity, aiming for a separate listing. This move creates India's largest omnichannel pharmacy platform with a revenue target of ₹25,000 crore by FY27. The promoter family will hold approximately 36.5% in the new company, with Shobana Kamineni as the executive...
Wockhardt activates Zaynich push, eyes global licensing deals
Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing deals while preparing for potential solo commercialization in key markets.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AQmcYDl
via...
After a robust march, pharma exports slow
India's pharmaceutical exports experienced a modest 1.5% growth in April and May, following a significant 31.2% surge in March driven by year-end targets and anticipation of US tariffs. Despite pricing pressures and regulatory scrutiny, shipments to the US rose 20.4% to $10.5 billion.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6crY4N
via...
Torrent Pharma set to finalise JB Chemicals buyout in 15-18 months
Torrent Pharmaceuticals is set to acquire JB Chemicals & Pharmaceuticals, with the deal expected to finalize in 15-18 months, pending regulatory approvals. The acquisition, primarily debt-funded, aims to enhance Torrent's presence in the Indian market, particularly in high-growth segments like cardiac and gastroenterology.
from Healthcare/Biotech-Industry-Economic...
Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection
Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29...
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth.
from...
Clear & Legible: Labelling on drug packets to get a booster
Concerns arose regarding medicine labels. Consumers struggled to read expiry dates. The shiny surface of strips posed readability issues. The Drugs Consultative Committee addressed the matter. A sub-committee will examine packaging in detail. They will assess regulations for packaging suppliers. The government considers voice-assisted QR codes. Braille...
Torrent Pharma to buy controlling stake in JB Chemicals from KKR for Rs 25,689 crore
Torrent Pharmaceuticals is set to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR for ₹11,917 crore, valuing JB Pharma at ₹25,689 crore. Following the acquisition, Torrent plans a merger, pending regulatory approvals, and will launch an open offer to public shareholders.
from Healthcare/Biotech-Industry-Economic Times...
Torrent, JB Chemicals finalising steps for two-stage merger, combine may find place in pharma big 5
Torrent Pharmaceuticals and JB Chemicals & Pharmaceuticals are finalizing merger terms in a two-stage deal. Torrent will first acquire KKR's 47.84% stake in JB Chemicals for approximately ₹13,433 crore, financed by global banks, potentially triggering an open offer. The subsequent merger aims to create synergies, positioning Torrent among India's...
From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations
Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide...
Eli Lilly to roll out diabetes medicine in prefilled pen
Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of...
Lupin launches generic chronic constipation treatment drug in US
Mumbai-based Lupin Ltd has introduced its generic Prucalopride tablets in the United States. This launch follows approval from the US health regulatory body. The tablets, available in 1 mg and 2 mg strengths, treat chronic idiopathic constipation in adults. These tablets are bioequivalent to Takeda Pharmaceuticals' Motegrity tablets.
from Healthcare/Biotech-Industry-Economic...
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly announced that India’s drug regulator has approved its Mounjaro KwikPen, a pre-filled injector pen for weight loss and diabetes treatment. Previously available only in vials, Mounjaro will now be offered in six dose strengths, enhancing convenience and competitiveness against Novo Nordisk’s newly launched Wegovy, which also features a user-friendly...
Pharma companies may lose licence if drugs fail tests
The health ministry is considering strict actions, including immediate license suspensions, for drugmakers producing substandard drugs. This proposal follows concerns about quality control and aims to safeguard public health. Pharma lobby groups have raised objections, citing technical issues and questioning the standards of government testing laboratories,...
Lupin gets USFDA nod for generic chronic constipation treatment drug
Lupin Limited has received the United States Food and Drug Administration approval for its generic version of Prucalopride tablets. These tablets are used for treating chronic idiopathic constipation. The approved strengths are 1 mg and 2 mg. This generic medicine is bioequivalent to Takeda Pharmaceuticals' Motegrity tablets. Lupin will manufacture...
Bharat Biotech, GSK to halve price of malaria vaccine by 2028
Drugmakers Bharat Biotech and GSK will reduce the price of their malaria vaccine, Mosquirix, to $5 per dose by 2028, more than halving the current cost. This price cut, driven by process improvements and expanded production, aims to improve access to the vaccine in sub-Saharan Africa, where malaria deaths are high. Gavi supports the vaccine's rollout...
China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs
Indian pharmaceutical and biotech sectors are experiencing early benefits from the global shift away from China, driven by the China+1 strategy. Companies are seeing increased conversion of inquiries into pilot projects and small contracts, particularly from large pharmaceutical firms seeking supply chain diversification.
from Healthcare/Biotech-Industry-Economic...
Weight-loss drug Wegovy starts at ₹17,345 in India
Novo Nordisk launches Wegovy, a weekly weight-loss injectable, in India. The drug is available in five dosages, costing between Rupees 17,345 and Rupees 26,015. It aims for chronic weight management and reduces cardiovascular risks. Experts highlight its potential despite the price. Mounjaro, another weight-loss drug, is priced lower. Weight-loss drugs...
A big fat fight has just broken out in India
India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and diabetes rates, with Mounjaro showing significant weight loss in trials. Wegovy boasts cardiovascular benefits and a competitive pricing strategy.
from Healthcare/Biotech-Industry-Economic...
Favipiravir drug shows promise against Chandipura virus in preclinical studies by NIV
Favipiravir offers hope against the Chandipura virus. Studies by the National Institute of Virology show promising results. The drug reduces viral load in infected animals. Chandipura outbreaks have occurred in India, affecting children. A major outbreak happened in 2024. Clinical trials on humans are pending. Research is underway for a vaccine. Current...
Novo Nordisk aims for heavy sales in India with Wegovy
The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescription brand sales. Keytruda, a breakthrough anti-cancer drug from MSD India (part of the US Merck group), is currently the No. 1 in prescription brands, with annual revenue exceeding Rs 1,600 crore, according to market...
Sickle cell anaemia test kits priced less than Rs 50 in govt's bid to eradicate the disease
Sickle cell anaemia diagnosis is now more accessible in India. The government reduced the price of diagnostic kits to under Rs 50. ICMR validated 35 point-of-care tests. This follows a health technology assessment. The National Health Mission instructed states to procure kits at lower prices. This initiative supports the National Sickle Cell Elimination...
ICMR's NIIH develops simple point of care test for haemophilia A, Von Willebrand Disease
A cost-effective point-of-care test kit has been developed in India for early diagnosis of haemophilia A and Von Willebrand Disease, offering a more accessible alternative to expensive lab tests. This innovation, costing just Rs 582 compared to Rs 2,086 for current methods, could detect over 83,000 undiagnosed cases and save the health system approximately...
From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations
Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide...
Amazon launches home diagnostic services in 6 cities through app
Amazon India has launched Amazon Diagnostics, an at-home lab test booking service, integrating it with Amazon Medical alongside Pharmacy and Clinic services. Partnering with Orange Health Labs, the service is available in major cities like Bengaluru, Delhi, Mumbai and Hyderabad, covering over 450 PIN codes. Customers can book tests, schedule appointments,...
From pimples to peptides: How Gen Z turned the dermatologist into a beauty guru
Urban India witnesses a surge in dermatology clinic visits, driven by teenagers and young adults seeking solutions for everyday skin concerns beyond chronic conditions. Social media influence and access to information fuel this trend, with consumers actively choosing science-backed skincare. This shift reflects a broader movement towards evidence-based...
Deadline diet India's young workforce faces cardiac scare
Young Indians are increasingly facing heart issues. Doctors report a rise in cardiac cases among those in their 20s and 30s. Stress, lack of sleep, and unhealthy lifestyles are major factors. Sedentary jobs and poor diets contribute to the problem. Even post-Covid inflammation increases the risk. Sales of heart-related drugs have significantly increased.
from...
Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for Rs 724.9 cr
Emcure Pharmaceuticals will acquire the remaining 20.42% stake in Zuventus Healthcare Ltd from minority shareholders for ₹724.9 crore, a move approved by its board. This acquisition, expected to close in the September quarter of FY26, will make Zuventus a wholly-owned subsidiary. Emcure aims to fully consolidate Zuventus financially, driving long-term...
Stress at work? Doctors see rise in heart diseases among young executives
Young Indians are increasingly facing heart issues. Cardiologists are alarmed by the rising cases in people in their 20s and 30s. Stress, sleep deprivation, and unhealthy lifestyles are major contributors. Hospitals report more young professionals with cardiovascular diseases. Experts suggest early screenings and lifestyle changes. Companies are now...
The Wegovy effect: A weight-loss drug reshapes the lives of teens battling obesity
Facing relentless bullying and health issues linked to obesity, some American teens are turning to Wegovy, a weight-loss drug initially approved for adults. While many see it as a chance for a healthier future, concerns linger about long-term safety and potential side effects. The experiences of four teens highlight both the benefits and challenges...
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The company is prioritizing meeting the growing demand for the diabetes and weight-loss drug in the country, where obesity and diabetes rates are rising.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MHEYcfC
via...
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus. An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021...
Global Autism Therapy Framework for 90 crore children: How India cracked 144-year-old world problem,
Pinnacle, an Indian autism therapy network, gains global recognition. It is acknowledged for its innovative, mother-led, and AI-enabled approach. International institutions and organizations are seeking collaborations. Pinnacle's framework is adaptable and inclusive. It focuses on measurable care and dignity-first delivery. The model is designed for...
6 anti-cancer foods to add to your daily chai
Make your chai time healthier by adding foods known to offer anti-cancer benefits. These simple, everyday ingredients can help fight harmful cells, boost immunity, and support overall well-being while you enjoy your cup of tea.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GU9nDfs
via IFT...
With no upgradation plan, several small drug companies may shut operations
Many small pharma companies in India may shut down. They did not meet the deadline for upgrading facilities. This is as per new Good Manufacturing Practices. Only 1,700 out of 6,000 units submitted upgrade plans. Closures could lead to job losses. There are also concerns about potential drug shortages and price increases. The government may initiate...
Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India
Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the extended-release version, marketed as Januvia, Janumet, and Janumet XR. This collaboration aims to leverage Abbott's extensive reach to ensure continued access to...
Suraksha Diagnostics to invest Rs 200 cr to set up over 20 centres across east India
Suraksha Diagnostics plans a significant expansion. The company will invest Rs 200 crore. This investment will establish over 20 advanced imaging centers. These centers will be located across eastern India. The expansion aims to improve diagnostic services. It will focus on tier 2 and tier 3 cities. This initiative will enhance healthcare access in...
Glenmark gets five observations from USFDA for Monroe plant
Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant received a Form 483 with five observations from the USFDA following a GMP inspection conducted in June 2025. The company stated that the observations are procedural and don't involve data integrity issues. Glenmark is committed to addressing the concerns and will...
Torrent Pharma keen to break into big league
Torrent Pharma, currently seventh in India, is aimingto break into the top three drugmakers within five years through strategic acquisitions. Bolstered by consistent growth in the Indian market, the company plans further investments following past deals like Curatio Healthcare. Expansion includes doubling its medical representatives to 7,000 for better...
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030.
from Healthcare/Biotech-Industry-Economic...
Zydus Healthcare appoints Swati Dalal MD
Zydus Lifesciences Ltd. has appointed Swati Dalal as an additional director and Managing Director of its subsidiary, Zydus Healthcare Ltd., effective June 16, 2025, for a five-year term. Dalal brings over 30 years of experience, most recently serving as Managing Director of Abbott India Ltd. Her career includes leadership roles at Wockhardt Nutrition,...
Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler
Lupin Limited partners with Sino Universal Pharmaceuticals. They will commercialize Tiotropium dry powder inhaler in China. This inhaler treats Chronic Obstructive Pulmonary Disease. Sino Universal will seek regulatory approvals. Lupin will manufacture the product. This collaboration expands Lupin's presence in China. It aims to improve respiratory...
Online pharmacies could face stricter check-ups
Amid rising concerns over unverified prescriptions and a surge in online pharmacies, the government is intensifying regulation and scrutiny on platforms promising medicine delivery within minutes. Complaints regarding bypassed safeguards like age verification have prompted this action.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MY96ZRe
via...
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma gets eight observations from USFDA for Halol plant
Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. The USFDA conducted a Good Manufacturing Practices (GMP) inspection at the facility from June 2-13, 2025. The Form 483, issued at the inspection's conclusion, highlights conditions that may violate the Food, Drug,...
Delhi HC refuses to halt Sun Pharma’s Pruease tables sales over trademark row
The Delhi High Court has denied RSPL Health's petition to stop Sun Pharmaceutical Industries from selling Pruease tablets, a constipation relief medication. RSPL Health, which sells sanitary napkins under the trademark 'Pro-ease,' claimed trademark infringement. The court dismissed the plea, stating that the products have distinct trade channels and...
Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes...
Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea
Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial...
Pharma body opposes entry curbs on medical representatives, seeks rethink
The Indian Pharmaceutical Alliance (IPA) voices concerns over the government's ban on medical representatives in central hospitals, arguing it hinders knowledge dissemination and patient care. IPA urges a structured engagement model, citing potential impacts on pharmaceutical growth, job losses, and the introduction of new therapies. They emphasize...
Niti Aayog may prescribe major revamp of AIIMS Delhi
Niti Aayog is expected to propose a major overhaul of AIIMS Delhi, including expanding its clinical services across the NCR to ease infrastructure pressure and allow doctors to focus more on research. A VK Paul-led committee is preparing a blueprint to reform AIIMS to global standards, with plans to utilize other government or private hospital spaces...
Glenmark to launch DCGI-approved cancer drug in India
Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings,...
Advent International to acquire stake in Felix Pharmaceuticals
Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support...
KKR-backed IVI to buy ART Fertility clinics for $450 million
IVI RMA Global, backed by KKR, is poised to acquire ART Fertility Clinics for $400-450 million, marking a significant expansion into India's burgeoning IVF market. This acquisition will add India to IVI RMA's global presence. The deal highlights the ongoing consolidation in the Indian IVF sector, driven by increasing infertility rates and private equity...
One cough too many: India's TB fight isn't quite there yet
Despite India's commitment to eliminate TB by 2025, the nation grapples with a significant burden of drug-resistant cases and underreporting. Stories like Anushka's highlight the challenges in accessing effective treatments and the critical need for improved diagnostics, funding, and equitable care.
from Healthcare/Biotech-Industry-Economic Times...
API prices fall sharply, easing pressure on India's pharmaceutical industry
India's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and aggressive pricing strategies from Chinese suppliers. Increased domestic API production, driven by government incentives and reduced raw material costs, further contribute to the decline. This trend is expected to...
Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.
from Healthcare/Biotech-Industry-Economic...
Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe
Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via...
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization...
Avoid crowded places: Union Health Ministry amid surge in COVID-19 cases
India faces a rise in Covid-19 cases. The Health Ministry advises avoiding crowds and maintaining hygiene. Technical reviews and preparedness measures are underway. Surveillance for ILI and SARI has increased. Testing and genome sequencing are in progress. States are instructed to ensure resource availability. Mock drills are planned to assess oxygen...
Murae Organisor board to consider bonus issue, dividend payout next week
Murae Organisor's board will convene on June 13 to deliberate on a bonus issue of equity shares and dividend payment for FY25. The company is also eyeing strategic business expansion, including investments in agro and distillery sectors. Furthermore, Murae Organisor has set June 11 as the record date for its 1:2 stock split, reporting a revenue of...
IIT Delhi and AIIMS Delhi to establish AI centre for healthcare with Rs 330 crore grant
IIT Delhi and AIIMS Delhi have partnered to establish a Centre of Excellence for Artificial Intelligence in Healthcare (AI-CoE), supported by a ₹330 crore government grant. The centre aims to develop AI-driven solutions to enhance healthcare access and delivery across India, focusing on key national health programs. This initiative seeks to improve...
Ujjain to host Spiritual & Wellness Summit, showcasing India’s holistic future
Ujjain is set to host the Spiritual & Wellness Summit on June 5, drawing spiritual leaders, wellness experts, and policymakers. Madhya Pradesh Chief Minister Mohan Yadav will inaugurate the summit, highlighting Ujjain's spiritual legacy. Panel discussions will explore collaborative frameworks harmonizing traditional health systems with modern wellness...
Biocon gets CDSCO nod for generic diabetes medication
Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly...
Medical representatives banned from visiting doctors in govt hospitals
The central government has banned medical representatives from directly meeting doctors in government hospitals to curb unethical practices and potential conflicts of interest. This decision aims to ensure doctors dedicate their time to patient care rather than promotional activities. The government encourages digital communication for sharing treatment...
Glenmark’s blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.
from Healthcare/Biotech-Industry-Economic...
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights...
Apollo Hospitals plans to sell maternity care arm
Apollo Hospitals Enterprises is planning to divest its maternity and infant care chain, Apollo Cradle and Children's Hospital (ACCHL). Allegro Capital has been appointed to find a buyer for ACCHL, with an estimated valuation of ₹1,000-1,200 crore. The sale process is underway, targeting leading private equity funds amidst a growing mother and child...
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D...
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older
Moderna's updated COVID-19 vaccine has received FDA approval for individuals aged 65 and older, marking the first endorsement under stricter regulatory guidelines. The vaccine is also authorized for those between 12 and 64 who have underlying health conditions that increase their risk. This approval signifies a step forward in protecting vulnerable...
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is...
Daiichi comments continue to damage interests: IHH Unit
Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for ₹11,800 crore. NTK alleges Daiichi Sankyo blocked its 2018 open offer for Fortis Healthcare. Daiichi Sankyo denies these claims. NTK seeks damages and an injunction against Daiichi Sankyo's statements. The next court hearing...
Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTK
IHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding the Fortis Healthcare open offer. NTK has increased its damages claim against Daiichi Sankyo to JPY 200 billion, alleging obstruction of the open offer's completion.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gBNxZ4I
via...
Flush expired, unused opioids down the toilet, says regulator
Drug regulatory authority mandates disposal of unused opioid drugs and painkillers. This action aims to prevent misuse and health risks. Central Drugs Standard Control Organisation has listed 17 harmful medicines for disposal. Some drugs should be flushed, while others can be collected through 'drug take back' programs. Unscientific disposal causes...
India gears up to reboot ICU standards, fix doctor drain, and cash in on global med travel
India is developing a structured critical care framework to bridge infrastructure and human resource gaps. Led by NITI Aayog, the initiative will define resource allocation, patient prioritization, and standards for critical care units nationwide. This aims to improve domestic healthcare and attract medical tourists, addressing current imbalances and...
Novartis offers payment plan for high-cost heart medicine
Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market...
Quadria's third fund nets $1 billion, to deploy 60% in India
Quadria Capital, an Asia healthcare-focused private equity firm, has successfully raised $1.07 billion for its third fund, surpassing its initial $800 million target. The oversubscribed fund will allocate approximately 60% of its capital to India, with the remainder invested in ASEAN countries. This fund also marks the first time Quadria Capital has...
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.
from Healthcare/Biotech-Industry-Economic...
VC funding, influencers power India’s health supplements craze amid lingering safety concerns
Fast forward to 2025, and a whole new market has emerged — gummies to enhance your hair health, powders to boost collagen, liquid for gut, pills for women’s perimenopause hormonal imbalance, magnesium tablets for better sleep, testosterone boosters, capsules with calming properties and vegan versions of all these.
from Healthcare/Biotech-Industry-Economic...
Dr Reddy's gets 2 observations from USFDA for Telangana API plant
Dr. Reddy's Laboratories received a Form 483 with two observations following a GMP inspection by the USFDA at its API manufacturing plant (CTO-5) in Miryalaguda, Telangana. The inspection, conducted from May 19 to May 24, 2025, identified potential violations of the Food Drug and Cosmetic Act. The company plans to address the concerns within the given...
China’s India Headache: The growing pharmaceutical industry
Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.
from...
Venus Remedies gets Ukrainian GMP renewal certification
Venus Remedies has received renewed GMP certification from Ukraine. This certification applies to its Baddi facility. It covers cephalosporin, non-cephalosporin, and oncology production lines. The company aims to strengthen its presence in Ukraine and PIC/S markets. This will facilitate international growth. The Ukrainian pharmaceutical market is expected...
Waive risk-based inspections, urges MSME pharma body
Laghu Udyog Bharati requests the government to waive risk-based inspections for companies upgrading their facilities. The association seeks an extension for Schedule M implementation for smaller firms. Concerns arise over inspections being conducted like raids. LUB highlights the role of MSMEs in supplying medicines during Covid. They request special...
Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc
Sun Pharmaceutical Industries Ltd will invest up to USD 25 million in Pharmazz Inc, increasing its stake to 22.7%. This investment triggers the conversion of a previous agreement. Sun Pharma gains an option to negotiate licensing of Sovateltide for developed markets and already holds exclusive rights for emerging markets. Pharmazz is developing drugs...
Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
Alembic Pharmaceuticals announced that it has secured final approval from the USFDA for its generic amlodipine and atorvastatin tablets, used for treating hypertension. The approval covers multiple strengths of the tablets, therapeutically equivalent to Pharmacia and Upjohn Co LLC's Caduet. With this approval, Alembic now has a cumulative total of...
Zydus working on single pen device for adjustable Semaglutide doses
Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both diabetes and obesity. Clinical trials are underway in India. Zydus plans a day 1 launch in India. They will explore partnerships for emerging markets. The device aims to improve patient convenience. Some companies...
Many MSME pharma firms making substandard drugs, CDSCO data shows
Data from the CDSCO reveals that numerous MSME pharmaceutical companies in India are producing substandard drugs, failing to meet safety standards. Inspections have uncovered issues with infrastructure, quality management, and manufacturing processes. A significant percentage of MSMEs have faced stop production orders due to these quality concerns,...
Neuberg, Star Imaging in joint venture to expand integrated diagnostics across Maharashtra
Neuberg Diagnostics and Star Imaging have partnered to expand integrated diagnostic centers across Maharashtra, aiming to unify radiology, pathology, wellness, and genomics for improved accuracy and faster diagnoses. This joint venture will establish a comprehensive, technologically advanced network, launching new centers in key cities like Pune and...
Bharat Biotech's cholera vaccine successfully completes Phase-III trials
Bharat Biotech's oral Cholera Vaccine, Hillchol, has successfully completed phase III clinical trials, demonstrating non-inferiority against Ogawa and Inaba serotypes in Indian adults and children. The study involved 1,800 participants across various age groups and ten clinical sites in India. With a production capacity of 200 million doses, Hillchol...
Aman Mehta appointed Managing Director of Torrent Pharma
Torrent Pharmaceuticals has appointed Aman Mehta, son of current chairman Samir Mehta, as Managing Director, effective August 1, 2025. This move marks the third-generation leadership taking charge, building upon the legacy of founder Uttambhai Nathalal Mehta. Aman's experience includes successful integration of acquisitions and strategic roles across...
IHH Healthcare increases damages claim against Daiichi Sankyo to Rs 11,800 cr over Fortis acquisition dispute
IHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to approximately Rs 11,800 crore. This revision follows Daiichi Sankyo's alleged interference with IHH's bid to acquire a larger stake in Fortis back in 2018. The increased claim accounts for losses and reputational...
Domestic drug companies in a sweet spot as global players look beyond insulin
Indian drug companies are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin and more type 1 diabetes cases are helping them. Domestic companies accounted for 25% of the market. Multinational companies are shifting focus. This shift creates opportunities for Indian companies. Lupin...
India's orthopaedic and cardiac implant sector to touch $4.5-5 bn by FY28: Report
India's implant sector is set for significant growth. The orthopaedic and cardiac implant market may hit USD 5 billion by FY28. Domestic manufacturers are expanding rapidly. They are outpacing foreign companies. Government initiatives and healthcare improvements are fueling this surge. Zydus Lifesciences and Alkem Laboratories are investing in this...
Non-AI organisations won't make it to 2050, says Diogo Rau
Eli Lilly's Diogo Rau emphasizes the critical role of AI in the pharmaceutical industry's future, predicting that companies not investing in AI now may not survive by 2050. Rau highlights AI's potential in drug discovery, including designing proteins and identifying promising molecules. He notes the challenge of limited datasets and the importance...
Dr Reddy's gets 2 observations from USFDA for New York API plant
Dr. Reddy's Laboratories announced that the USFDA issued a Form 483 with two observations after a GMP inspection of its API manufacturing facility in Middleburgh, New York. The inspection, conducted between May 12-16, 2025, identified potential violations of the Food Drug and Cosmetic Act.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pfM1h8q
via...
'Irrational' fixed dose combos harmful, may face ban: Expert panel
Several personal care products containing ingredients like aloe vera, jojoba oil, and orange oil are likely to be banned in India. An expert committee has deemed these fixed-dose combinations (FDCs) as irrational and potentially harmful to human health.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ofjYH2
via IFT...
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue...
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.
from...
Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran Shaw
Biocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity, aiming to improve profitability. The company is also considering a merger with its parent company as an alternative to an IPO due to market uncertainties.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaU2g47
via...
Donald Trump’s order to lower prices may benefit generics, says Cipla CEO
Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.
from...
US govt order to have nil impact on Indian pharma players, says Cipla
Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments...
Lupin launches generic version of kidney disorder treatment drug in US
Lupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, are bioequivalent to Jynarque and indicated for slowing kidney function decline in adults with ADPKD. Lupin holds exclusive first-to-file status, granting them 180-day generic drug exclusivity.
from...
Trump drops the price bomb, Indian pharma may feel aftershock
President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.
from...
India has not accepted 'data exclusivity' demand by UK to protect generic drug firms
India has declined the UK's request for a 'data exclusivity' clause in their free trade agreement to safeguard its domestic generic drug industry. This decision mirrors a previous rejection of a similar demand from the EFTA bloc. The move aims to protect the flourishing generic drug sector, a key player in India's exports, from potential restrictions...
Trump's drug order sparks concern for India's pharma policy: GTRI
Donald Trump's "Most Favored Nation" pricing rule, aimed at significantly lowering U.S. drug prices, is expected to have global repercussions. The move could pressure pharmaceutical companies to seek higher revenues in markets like India, potentially impacting its pharmaceutical policies.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UXRAgN4
via...
Biocon plans $150-million capex in two years
Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future...
Dr. Reddy's eyes aspirational goal to be in top five in the Indian market
Dr. Reddy's Laboratories is prioritizing innovative product launches through strategic partnerships to achieve a 15-16% growth in the Indian market. The company's focus includes expanding its portfolio with new products, growing existing brands, and strengthening its consumer health segment. Recent successes include the launch of toripalimab and upcoming...
FDC recalls over 60,000 bottles of ophthalmic solution in US
FDC Ltd is recalling over 60,000 bottles of Timolol Maleate Ophthalmic Solution, a generic glaucoma medication, in the US market. The USFDA reported the recall, initiated on April 18, is due to a defective container issue where the bottle's spike was lodged in the nozzle, preventing solution dispensing.
from Healthcare/Biotech-Industry-Economic Times...
Zydus gets USFDA nod for generic drug to treat multiple sclerosis
Zydus Lifesciences has secured USFDA approval to market Glatiramer Acetate Injection, a generic version of Copaxone, for treating relapsing forms of Multiple Sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, the drug addresses a market with USD 719 million in annual sales in the US. This approval highlights Zydus' dedication to providing...
Generic versions of key diabetic drug in market double in a month
Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for Indian patients. Prices have dropped significantly, increasing access. Doctors are optimistic about the future. More patent expirations will further benefit...
Mounjaro is now a heavyweight in weight-loss fight
Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections increased significantly in April. Doctors are observing its effectiveness and side effects on Indian patients. Obesity is prevalent in India. Affordability and tolerance are key factors. Studies suggest constipation is a common side...
Aster DM Healthcare to invest Rs 480 cr to set up new hospital in Bengaluru
Aster DM Healthcare will invest Rs 480 crore to establish a 430-bed multispecialty hospital in Sarjapur, Bengaluru. The hospital, spanning 4 lakh sq ft, will be developed in two phases, with 300 beds operational by the second half of FY27 and the remaining 130 beds by FY29.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PX0s9jY
via...
Trump's new executive orders may hit Indian Pharma exports, reshape global drug supply chains: Report
The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gEMCJw8
via IFT...
Trump's prescription: Indian drug units may face stricter check-ups
Following President Trump's executive order, the Indian pharmaceutical industry anticipates a surge in unannounced inspections by the US FDA, causing concerns about compliance and potential trade barriers. Experts suggest that companies should diversify their business and invest in innovation to mitigate risks associated with increased scrutiny and...
TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India
TPG Growth is set to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, with Novo Holdings co-investing. This deal aims to bolster the drug containment firm's growth in India and globally. Serum Institute will retain a minority stake, while SCHOTT Pharma remains the controlling stakeholder, leveraging TPG's healthcare expertise.
from...
Revised rules for biosimilar drugs enter the final stretch
The Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and manufacturing. These revised 'Guidelines on Similar Biologics' prioritize minimizing animal testing, advocating for in-vitro studies and the 3R principles (replace, reduce, refine). The aim is to balance regulatory...
Biocon Biologics secures multiple market access agreements in US for Yesintek
Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Multiple formularies, including Express Scripts, Cigna, and UnitedHealthcare, will include Yesintek starting in 2025. This approval expands affordable treatment options for Crohn's disease, ulcerative colitis, plaque...
Manipal, IHH, EQT & others eye Sahyadri Hospitals in Rs 5,000 crore bidding war
Manipal Hospitals, IHH Healthcare, and Blackstone-owned Quality Care India are among the frontrunners vying for Sahyadri Hospitals, Maharashtra's largest hospital chain, with bids ranging from ₹4,500-5,000 crore. Ontario Teachers’ Pension Plan Board is divesting the chain amid a wave of PE-led consolidation in India's rapidly growing healthcare sector,...
Panel to take a call on doorstep medicine delivery
India's drug advisory body is considering the future of doorstep medicine delivery, initiated during the Covid-19 pandemic. The All-India Organisation of Chemists and Druggists is urging the government to withdraw the notification, alleging misuse by digital platforms and prioritizing profit over patient safety. A sub-committee will now examine the...
With weight-loss drugs, going under the knife may lose edge
The introduction of weight-loss medications like Mounjaro and Wegovy in India may lead to a decrease in bariatric surgeries as obese individuals with a BMI of 30-35 may opt for drugs first. While surgeries can result in 70-80% weight loss, drugs offer a less invasive option, though potentially less effective at 15-20%.
from Healthcare/Biotech-Industry-Economic...
Alembic gets USFDA nod for generic drug
Alembic Pharmaceuticals secured USFDA approval to market generic Ticagrelor tablets, 90 mg, aimed at preventing heart attack and stroke. They also received tentative approval for the 60 mg version. The approved drug is equivalent to AstraZeneca's Brilinta, with the 90 mg tablet having a market size of over USD 1 billion.
from Healthcare/Biotech-Industry-Economic...
Opioid Tapentadol may be put under Narcotics Act to curb its access
The government is planning to regulate Tapentadol under the Narcotic Drugs and Psychotropic Substances Act. This follows concerns about its misuse and exports to West Africa. The move aims to control its availability. The Narcotics Control Bureau and police will oversee its movement. Tapentadol is a pain management drug with limited alternative treatment...
Ranitidine ban deferred despite cancer concerns
Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous tests revealed that many Ranitidine samples contained unsafe levels of NDMA impurities. The ICMR has been asked to conduct a study to assess the drug's...
BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts
BDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million investment. Chairman Dharmesh Shah mentioned the company is evaluating potential units and expects a decision within months, funded by internal accruals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cK9xTlR
via...
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India through share swap
Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug
Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million,...
Max Healthcare lines up Rs 6,000 crore for expansion
Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pnvJMtA
via I...
Max Healthcare Institute to invest Rs 6,000 cr to add 3,700 beds by 2028
Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic...
Medanta to invest Rs 500 cr to set up 400-bed hospital in Guwahati
Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million...
Dr Reddy's to introduce Sanofi's novel drug in India
Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing lower respiratory tract disease in newborns caused by RSV. Dr. Reddy's will exclusively promote and distribute Beyfortus in India, with a launch expected in the second quarter of the current fiscal year, following regulatory...
Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itself
A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SMA), potentially earning 115 times its clinical trial expenses. Knowledge Ecology International estimates trial costs at $50 million, while Roche's risdiplam revenue reached $5.8 billion. Roche defends its pricing,...
Get evergreening patent requests very often, these benefit select few cos: Piyush Goyal
Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as 'evergreening,' for prioritizing corporate profits over global healthcare access. Goyal highlighted Ayushman Bharat scheme, providing free healthcare to over 620 million people. He emphasized India's...
Zydus gets 6 observations from USFDA for API unit
Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug...
SS Innovations International to list on US exchange Nasdaq
SS Innovations International, an Indian surgical robotics company, is set to list on the Nasdaq under the ticker 'SSII' on April 25. The company experienced substantial revenue growth, reaching $20.6 million in 2024, a 3.5-fold increase from the previous year.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MAwe3r7
via IFT...
Reckitt Benckiser's rare reflection: India a big growth driver
Reckitt Benckiser's CEO, Kris Licht, highlights India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals, through initiatives like 'Dettol...
To speed up delivery, govt exempts orphan drugs from testing at ports
To ensure timely access to life-saving orphan drugs for patients, the government has exempted mandatory sampling and testing at port offices. The drug regulator will now release consignments based on a legal undertaking from the importer. This decision addresses challenges like small volumes and specialized testing needs, streamlining the process and...
Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively
The Delhi High Court has provided relief to pharma companies like Glenmark Pharmaceuticals and Zuventus Healthcare, ruling that the ban on fixed-dose combinations for children under four will be applied prospectively. The court directed companies to issue advisories to doctors and publish notices in national newspapers, informing that the drugs should...
Delhi HC orders cough syrup makers to warn against use in children below 4, issue public notices
Glenmark and Zuventus Healthcare have approached the Delhi High Court against the Centre’s April 15 notification banning the use of certain cough syrups for children below four years of age. The companies argued that the order should not apply retrospectively.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7BHbMS1
via IFT...
Drugs panel considering proposal to rein in sale of OTC medicines to prevent misuse
India's drug advisory board is considering restricting over-the-counter medication sales to prevent misuse and ensure patient safety. The proposal limits OTC sales to 27 drugs, including antipyretics and painkillers, with dosage and quantity restrictions. The board aims to increase accessibility while ensuring patient safety by excluding several currently...
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, used for treating specific bone marrow and blood cancers. The approved tablets, available in multiple strengths, are therapeutically equivalent to Bristol-Myers Squibb's Sprycel. Launch is anticipated in Q1FY26, targeting...
Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton Bharat
India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a 326% surge in values for Q1 2025. Despite a slight quarterly dip due to macroeconomic factors, high-value deals are on the rise, particularly in M&A and PE activity, signaling confidence in scalable models and...
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply...
Dr Reddy's, Lupin recall products in US due to labelling, manufacturing errors: USFDA
Dr. Reddy's Laboratories and Lupin are recalling products in the US due to labeling and manufacturing issues. Dr. Reddy's is recalling an antiepileptic drug due to a labeling mix-up, where infusion bags were incorrectly labeled. Lupin Pharmaceuticals is recalling an antidepressant medication due to failed impurity specifications. The USFDA has classified...
India faces a silent cervical cancer crisis: Every 8 minutes, a woman dies, but HPV vaccine and early screening could prevent it
The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve prevention and treatment in India. The organisation emphasised the importance of indigenous HPV tests and vaccines in cancer screening, alongside strengthening diagnostic infrastructure. Key recommendations include early detection,...
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become...
Russia-Ukraine war: Indian pharma firm caught in crossfire, lobby seeks PM Modi’s help
An Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly struck by a missile, prompting the Federation of Pharma Entrepreneurs to seek Prime Minister Modi's intervention.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKe1D3p
via IFT...
Shivinder Mohan Singh moves NCLT, files plea for personal insolvency
Shivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding assets. Facing a Rs 3,500 crore recovery to Daiichi Sankyo, Singh's assets are largely attached or devalued due to litigation and mismanagement within RHC Holding.
from Healthcare/Biotech-Industry-Economic Times...
Pharmacists seek clarity on banned cough syrup stock
Pharmacists are seeking clarification from the DCGI regarding the handling of recently banned cough syrups for children under four, specifically concerning existing stocks and prescriptions. The IPA has requested guidance on whether to return stocks or sell them until depleted, and if prescriptions for young children can be dispensed. The industry...
Centre pushes for 'one nation, one swap transplant' system to boost kidney donations
India is set to promote kidney swap transplants nationwide, aiming to increase transplant numbers by up to 15%. Following a directive from NOTTO, states and union territories are encouraged to implement swap transplants, a practice already recognized but underutilized. The initiative includes a standardized document list and the potential creation...
Yoga vs Strengthening exercises: Which is better for knee osteoarthritis? Study reveals surprising results
A recent study indicates yoga is as effective as strengthening exercises for managing knee osteoarthritis, offering improvements in pain, quality of life, and depression. Experts highlight yoga's comprehensive approach, addressing mental health, balance, and joint mobility. Both yoga and resistance training achieve similar physiological goals through...
US tariff chaos, global headwinds hit pharma GCC hiring in India
Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharmaceutical and healthcare GCCs. Experts predict a 6-7% reduction in net talent addition this fiscal year as companies adopt a cautious approach. Despite this temporary slowdown, India remains a vital hub for R&D, with long-term growth prospects fueled...
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially...
Health ministry in talks to shield India’s pharma industry amid impending tariffs from team Trump
India's health ministry is actively exploring strategies to protect its pharmaceutical industry from potential US tariffs. Discussions involve a fixed tariff regime and waiving import tariffs on US pharma products. The US is also raising concerns about nutraceutical imports, prompting India to consider regulatory changes, potentially impacting the...
Divi's Lab inks supply pact with global pharmaceutical entity
Divi's Laboratories announced a long-term supply agreement with a global pharmaceutical company, focusing on manufacturing and supplying advanced intermediates. The company anticipates significant revenue generation from this partnership.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KBMRzNm
via IFT...
Govt bans select cough syrups for kids below 4 years
The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four due to safety concerns. Drug regulators are mandating manufacturers to include explicit warnings on labels and packaging. This decision follows recommendations from India's apex drug body after examining the fixed-dose...
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has received the United States Food and Drug Administration approval. The approval allows them to market Carbamazepine tablets in the US. This medication is a generic version of Tegretol Tablets. Carbamazepine tablets are anticonvulsants. They also treat pain from trigeminal neuralgia. The market size for these tablets is estimated...
Assam govt plans to transform GMCH into one of India's largest hospitals
Assam Chief Minister Himanta Biswa Sarma is undertaking steps to transform Gauhati Medical College and Hospital into one of India's largest. The upcoming Mother and Child Care Hospital on GMCH premises will offer specialized pediatric care with 800 beds.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYoetgL
via IFT...
Trump’s executive order on drug pricing could be a booster for Indian pharma industry
Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtGwUZb
via IFT...
In major development in pharma, halt order enforced on production and sale of 35 fixed-dose combination drugs
India's drug regulator, CDSCO, has ordered a halt to the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs due to safety concerns. These drugs, including pain relievers and diabetes medications, lacked proper evaluation before approval. The CDSCO has directed state and Union territory regulators to reassess approval procedures,...
Mercury soars, and so do sales of rehydration drinks in India
India is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in March, leading the oral electrolyte market's growth. Doctors are reporting an increase in digestive disorder cases, further fueling the need for rehydration solutions as temperatures rise and waterborne diseases become...
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.
from...
Biocon Biologics secures market entry for Yesafili in US
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon Biologics to launch Yesafili in the US by the second half of 2026, or earlier under certain conditions. Yesafili, already approved by the USFDA, is intended...
Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 crore from Indian pharma giants
Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing...
Pharma companies may feel heat of US tariffs on China
India's pharmaceutical industry is bracing for potential disruptions due to US tariffs on Chinese goods. Experts warn that China may increase prices for key pharmaceutical ingredients exported to India to offset tariff costs. With India heavily reliant on China for APIs and intermediates, this could lead to higher medicine production costs.
from Healthcare/Biotech-Industry-Economic...
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claim
Dr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the company aimed to cut manpower expenses by 25%, prompting high-salaried employees, including those earning over ₹1 crore annually, to resign. Voluntary retirement was also reportedly offered to R&D employees aged...
Dr Reddy’s slashing jobs to cut costs by 25%; asks several Rs 1 crore+ earners to resign
Dr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, including those earning over ₹1 crore annually, are being asked to resign. The R&D division is offering voluntary retirement to employees aged 50–55. Some divisions, like digital therapeutics, may face shutdowns or...
India's healthcare expenditure expected to surge from 3.3% to 5% of its GDP by 2030: CareEdge
India’s healthcare spending is projected to rise from 3.3% to 5% of GDP by 2030, according to a CareEdge report. The sector is poised for major transformation driven by investments, government initiatives, and demographic shifts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ShcUkJe
via IFT...
Glenmark, Sun Pharma, Zydus recall products in US
Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the USFDA. Glenmark is recalling over 25 products, while Sun Pharma is recalling Gabapentin capsules due to cross-contamination. Zydus is recalling chlorproMAZINE Hydrochloride Tablets due to an impurity exceeding the...
Healthcare investors go for full-body check-up: Forensic due diligence rise as sector faces scrutiny
Investors are increasingly scrutinizing India's healthcare sector, including pharma companies and hospitals, due to concerns about potential malpractices and regulatory scrutiny. They are conducting in-depth due diligence, examining doctor-management relationships, referral practices, and the appropriateness of treatments. This heightened scrutiny...
Any tariffs on pharma sector would be counterproductive for Americans: Wockhardt Chairman Habib Khorakiwala
Wockhardt Chairman Habib Khorakiwala warns that potential US tariffs on pharmaceutical products would harm Americans. He highlights India's crucial role in supplying 40% of US prescription drugs at reasonable prices. Imposing tariffs would increase healthcare costs for Americans, given the lengthy FDA approval process and higher manufacturing and research...
Weight is over! Pharma companies race to make weight-loss drug semaglutide
Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic versions of Novo Nordisk's Wegovy and Ozempic as patents expire. These companies are developing novel technologies and aligning capacities for delivery pens, targeting both the Indian market and exports.
from Healthcare/Biotech-Industry-Economic...
USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm
Aurobindo Pharma Ltd announced that the USFDA issued a Form 483 with 11 observations following an inspection of its Aurolife Pharma LLC's Raleigh plant in North Carolina. The company stated that the observations are procedural and it will respond with corrective actions. Aurobindo Pharma anticipates no significant impact on its operations or supplies...
Morepen to hire 1,000 medical representatives to strengthen formulations biz
Morepen Laboratories plans to significantly expand its medical representative team, adding over 1,000 members in the next three years, with 200 joining in FY26. This strategic move aims to bolster its formulations business and capture a larger share of the growing Indian pharmaceutical market, targeting Rs 1,000 crore in five years.
from Healthcare/Biotech-Industry-Economic...